19th Ave New York, NY 95822, USA
Join Now

Gastrointestinal Tract Tumours Group

Portfolio Item Gastrointestinal Tract Tumours Group
CLINICAL RESEARCH

VHIO’s Colorectal Cancer Group, led by Elena Élez, has extensive experience in managing this disease. We (co) lead several clinical and translational research projects aimed at identifying novel prognostic and predictive biomarkers to help guide treatment decision making and expose mechanisms of drug resistance in colorectal cancer (CRC).

Our group is recognized as a reference in BRAF-mutated CRC research. This mutation is associated with aggressive clinicopathological and molecular features, including mucinous differentiation and microsatellite instability. Illustrating our efforts in this area, our investigators participated in the BEACON phase III landmark study that led to the approval of the BRAF inhibitor encorafenib in combination with cetuximab for the treatment of patients with BRAFV600E-mutated CRC. Furthermore, we have expanded our patient cohort of BRAF-mutated CRC through an investigator-initiated trial evaluating the efficacy of a novel drug combination —encorafenib, cetuximab and bevacizumab—in this setting.

We actively lead and participate in other important clinical studies aimed at expanding effective therapeutic strategies against metastatic CRC, including immune-based therapeutic combinations. Our drug development efforts have contributed to the approval of several targeted treatments, including trifluridine-tipiracil plus bevacizumab in refractory mCRC, pembrolizumab in MSI-H advanced CRC, and fruquintinib in refractory mCRC.

A key line of research that we intend to consolidate in the coming years is centered on early-onset CRC (EO-CRC). The rising global incidence in younger people (< 50 years old) remains an urgent concern. While the reasons for this alarming trend are not entirely clear, it is likely that there is an association with the environmental exposures that an individual experiences throughout their life (exposome), leading to genetic and epigenetic alterations in colorectal epithelial cells, the gut microbiota and host immunity. We aim to uncover mechanisms involved in the pathogenesis of CRC in younger patients and investigate the interplay of diverse driving factors.

The microbiome has been shown to play a key role in drug metabolism, efficacy, and toxicity, as well as cancer development. Our studies in this field leverage multidisciplinary collaborations and new approaches to integrate analysis of diverse biological samples (feces and saliva) and sophisticated experimental systems to probe their functionality.

Considering the mounting evidence demonstrating the importance of nutrition-microbiome interactions in cancer, we have designed a food frequency questionnaire (FFQ) to study the dietary patterns of the Spanish population and its impact on the intestinal microbiota. The questionnaire’s validity will be assessed by comparing the food and nutrient intake reported by patients with three-day food records in healthy individuals. Additionally, the reproducibility of the FFQ will be tested in patients diagnosed with colon cancer at the Vall d’Hebron University Hospital.

We are also developing specific projects in rectal cancer. Focused mainly on localized stages, these efforts aim to optimize perioperative treatment and surgery. Led by Jaume Capdevila, clinical trials have been developed for this patient population, including the DUREC study which has been designed to assess the addition of immunotherapy (durvalumab) to standard of care chemotherapy and radiotherapy to increase the probability of cure.

Translational efforts in rectal cancer also include microbiota analysis and its impact on rectal cancer treatment efficacy. Among other studies underway, we focus on studying the microbiota and its association with rectal cancer development and treatment response, and are leading the TAU-TEM study investigating early-stage disease, promoting collaboration with other disciplines including surgery and radiotherapy.

Elena Élez
Group leader
Biosketch

Research lines

  • Contribute to drug development in colorectal cancer (CRC) through our participation in optimally designed international and innovative clinical trials.
  • Study the mechanisms of cancer drug resistance in BRAF-mutated CRC.
  • Identify novel predictive biomarkers of treatment response.
  • Investigate early-onset CRC. Identify and understand the mechanisms involved, with particular emphasis on the impact of the microbiome.
  • Develop and implement new diagnostic approaches and tumor-on-a-chip models to study the CRC tumor microenvironment.
  • Characterize the potential of the gut microbiome as a determinant of treatment response or resistance and evaluate its therapeutic actionability in CRC.
  • Validate and assess the reproducibility of the food frequency questionnaire to study the dietary patterns of the Spanish population and its impact on the intestinal microbiota.
  • Study colorectal cancer liver metastases from different perspectives to deepen insights into their growth pattern and role as a prognostic factor.

Team

Group leader
Elena Élez
Colon Cancer Team: Medical Oncologists and Clinical Investigators
Iosune Baraibar
Marta Rodríguez
Francisco Javier Ros
Francesc Salvà
Nadia Saoudí
Research Oncology Nurse
Ariadna García
Research coordinator
Sebastián Guzmán
Colon Taskforce Manager
Mireia Sanchis
Nutritionist
Adriana Alcaraz
Rectal Cancer Team: Medical Oncologist and Senior Consultant
Jaume Capdevila
Medical Oncologists
Jorge Hernando
Alejandro García
Research Oncology Nurse
Ana Vazquez
Sample Manager
Inés Suárez

Projects

Título: Biomarker indentification in patients with BRAF mutant metastatic colorectal cancer to guide treatment strategy and overcome primary/adquired restances to BRAF Inhibior-targeted agents (BRAFsistance). Entidad Financiadora: Fundación CRIS. Periodo de Ejecución: 1/05/2024-30/04/2029. PI: Elena Élez

Título:  Evaluación de las estructuras linfoides terciarias (TLS) como biomarcador en el cáncer colorrectal metastásico tratado con combinaciones de puntos de control inmunitarios. Entidad Financiadora: Fundación SEOM. Periodo de Ejecución: 1/12/2023-30/11/2025. PI: María Elena Élez

Título: Uso de estreptozotocina en pacientes con tumores neuroendocrinos bien diferenciados: datos de la vida real y comparación con esquemas de quimioterapia basados en temozolomida. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024. PI: Alejandro García

Título: Eficacia de las diferentes secuencias de tratamiento con inhibidores multikinasa en pacientes con carcinoma diferenciado de tiroides en el registro regetne-tiroides. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024. PI: Alejandro García

Publications

Most relevant scientific publications

  1. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53.
  2. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667.
  3. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May;24(5):496-508.
  4. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 Jun;34(6):543-552.

 

All publications

  1. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
  2. Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul;35(7):643-655. doi: 10.1016/j.annonc.2024.03.009.
  3. Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736.
  4. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Erratum in: Nat Commun. 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9.
  5. Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409.
  6. Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2024 Jan 17;30(2):436-443. doi: 10.1158/1078-0432.CCR-23-1379.
  7. Martínez-Quintanilla J, Cabot D, Sabia D, Arqués O; PMPnet Group; Vergés J, Chicote I, Bijelic L; PMPnet Group; Cabellos L, Alcántara AM, Ramos I, Barrios P, Crusellas O, Palacio LM; PMPnet Group; Cámara JA, Barriuso J; PMPnet Group; Jiménez JJ, Muñoz-Torres P, Nonell L, Flores R, Médico E, Guaglio M; PMPnet Group; Ros J, Élez E, Tabernero J, Aziz O, Deraco M, Palmer HG; PMPnet Group; PMPnet Group. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. Clin Cancer Res. 2024 Sep 13;30(18):4082-4099. doi: 10.1158/1078-0432.CCR-23-4072.
  8. Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer. EBioMedicine. 2024 Oct;108:105352. doi: 10.1016/j.ebiom.2024.105352.
  9. Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290.
  10. Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458.
  11. García-Alfonso P, Elez E, Soto-Alsar J, Páez D, Fernández-Montes A, Graña B, Salud A, Yubero A, Gómez-España MA, Macías I, Quintero G, López-López C, Fernández-Rodríguez T, Grávalos C, González-Flores E, Guix M, García Paredes B, Reina JJ, Rodríguez Mowbray JR, Sastre J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024 Dec;9(12):103986. doi: 10.1016/j.esmoop.2024.103986.
  12. Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley MJ, Elez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper ZA, Kumar R, Tabernero J. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. Br J Cancer. 2024 Oct;131(6):1005-1013. doi: 10.1038/s41416-024-02796-3.
  13. Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B, Alcasid A, Zhang X, Van Cutsem E. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. BMC Cancer. 2024 Apr 11;24(1):446. doi: 10.1186/s12885-024-12153-5.
  14. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Élez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100.
  15. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249.
  16. García-Alfonso P, Vera R, Aranda E, Élez E, Rivera F. Delphi consensus for the third-line treatment of metastatic colorectal cancer. Clin Transl Oncol. 2024 Jun;26(6):1429-1437. doi: 10.1007/s12094-023-03369-1.
  17. Salvà F, Saoudi N, Rodríguez M, Baraibar I, Ros J, García A, Tabernero J, Elez E. Determinants of Metastatic Colorectal Cancer With Permanent Liver- Limited Disease. Clin Colorectal Cancer. 2024 Sep;23(3):207-214. doi: 10.1016/j.clcc.2024.05.010.
  18. Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, Alcaraz A, Salva F, Tabernero J, Elez E. Targeting KRASG12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms25063304.
  19. Salva de Torres C, Baraibar I, Saoudi González N, Ros J, Salva F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer. Int J Mol Sci. 2024 Jun 26;25(13):6967. doi: 10.3390/ijms25136967.
  20. Saoudi González N, Ros J, Baraibar I, Salvà F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers (Basel). 2024 Jan 18;16(2):412. doi: 10.3390/cancers16020412.
  21. González NS, Marchese PV, Baraibar I, Ros J, Salvà F, Rodríguez M, Salvà C, Vaghi C, Alcaraz A, García A, Tabernero J, Élez E. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert Opin Investig Drugs. 2024 Jun;33(6):613-625. doi: 10.1080/13543784.2024.2349287.
  22. Contreras-Toledo D, Jiménez-Fonseca P, López CL, Montes AF, López Muñoz AM, Vázquez Rivera F, Alonso V, Alcaide J, Salvà F, Covela Rúa M, Guillot M, Martín Carnicero A, Jimeno Mate R, Cameselle García S, Asensio Martínez E, González Astorga B, Fernandez-Diaz AB, González Villaroel P, Virgili Manrique AC, Melián Sosa M, Alonso B, Cousillas Castiñeiras A, Castañón López C, Aparicio J, Carmona-Bayonas A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist? Br J Cancer. 2024 Mar;130(5):777-787. doi: 10.1038/s41416-023-02563-w.
  23. Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.
  24. Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment. Biomed Pharmacother. 2024 Jul;176:116857. doi: 10.1016/j.biopha.2024.116857.
  25. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dienstmann R, Tabernero J, Vivancos A, Elez E. Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]. Ann Oncol. 2024 Oct;35(10):922. doi: 10.1016/j.annonc.2023.07.010. Epub 2024 Aug 12. Erratum for: Ann Oncol. 2023 Jun;34(6):543-552.
  26. García-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, Ghanem I, Pulido Cortijo G, Mariño Méndez A, Pazo-Cid R, Vera R, Melián M, Alcaide J, Graña B, Páez D, Gallego I, Lobo M, Borregón M, Fernández Montes A, Martínez de Castro E, Carmona-Bayonas A, Aranda E. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. Oncologist. 2024 Nov 16:oyae300. doi: 10.1093/oncolo/oyae300.
  27. Ros J, Ucha JM, Garcia-Galea E, Gomez P, Martini G, Balconi F, Comas R, Alonso V, Rodriguez M, Baraibar I, Salva F, Saoudi N, Alcaraz A, Garcia A, Tabernero J, Elez E. Real-World Data of Patients with BRAFV600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. Cancers (Basel). 2024 Dec 12;16(24):4140. doi: 10.3390/cancers16244140.
  29. Fruquintinib versus placebo in patients with refractory metastatic colorectal  cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase  3 study..Dasari, Arvind ; Lonardi, Sara ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Sobrero, Alberto ; Yao, James ; García-Alfonso, Pilar ; Kocsis, Judit ; Cubillo Gracian, Antonio ; Sartore-Bianchi, Andrea ; Satoh, Taroh ; Randrian, Violaine ; Tomasek, Jiri ; Chong, Geoff ; Paulson, Andrew Scott ; Masuishi, Toshiki ; Jones, Jeremy ; Csoszi, Tibor ; Cremolini, Chiara ; Ghiringhelli, Francois ; Shergill, Ardaman ; Hochster, Howard S ; Krauss, John ; Bassam, Ali ; Ducreux, Michel ; Elme, Anneli ; Faugeras, Laurence ; Kasper, Stefan ; Van Cutsem, Eric ; Arnold, Dirk ; Nanda, Shivani ; Yang, Zhao ; Schelman, William R ; Kania, Marek ; TABERNERO CATURLA, JOSEP; Eng, Cathy ; FRESCO-2 Study Investigators.LANCET.1.1.168,9.13.10.1016/S0140-6736(23)00772-9
  30. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer..Hadoux, Julien ; Elisei, Rossella ; Brose, Marcia S ; Hoff, Ana O ; Robinson, Bruce G ; Gao, Ming ; Jarzab, Barbara ; Isaev, Pavel ; Kopeckova, Katerina ; Wadsley, Jonathan ; Führer, Dagmar ; Keam, Bhumsuk ; Bardet, Stéphane ; Sherman, Eric J ; Tahara, Makoto ; Hu, Mimi I ; Singh, Ravinder ; Lin, Yan ; Soldatenkova, Victoria ; Wright, Jennifer ; Lin, Boris ; Maeda, Patricia ; CAPDEVILA CASTILLON, JAUME; Wirth, Lori J ; LIBRETTO-531 Trial Investigators.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5.7.10.1056/NEJMoa2309719
  31. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal  Cancer..Prager, Gerald W ; Taieb, Julien ; Fakih, Marwan ; Ciardiello, Fortunato ; Van Cutsem, Eric ; ELEZ FERNANDEZ, MARIA ELENA; Cruz, Felipe M ; Wyrwicz, Lucjan ; Stroyakovskiy, Daniil ; Pápai, Zsuzsanna ; Poureau, Pierre-Guillaume ; Liposits, Gabor ; Cremolini, Chiara ; Bondarenko, Igor ; Modest, Dominik P ; Benhadji, Karim A ; Amellal, Nadia ; Leger, Catherine ; Vidot, Loïck ; TABERNERO CATURLA, JOSEP; SUNLIGHT Investigators ; Amann, Arno ; Gerger, Armin ; Greil, Richard ; Gruenberger, Birgit ; Popper, Ulrich ; Prager, Gerald ; Winder, Thomas ; Hendrickx, Koen ; Houbiers, Ghislain ; Lybaert, Willem ; Peeters, Marc ; Van Custem, Eric ; Abdalla, Káthia Cristina ; Campos Bragagnoli, Arinilda ; Carmagani Pestana, Roberto ; Cruz, Felipe José Silva Melo ; Spina Donadio, Mauro Daniel ; Fernandes, Gustavo Dos Santos ; Moniz, Camila Motta Venchiarutti ; Liposits, Gabor Istvan ; Olesen, Rene ; Petersen, Lone Nørgård ; Pfeiffer, Per ; Borg, Christophe ; Boussion, Helene ; Galais, Marie-Pierre ; Poureau, Pierre-Guillaume ; Taieb, Julien ; Tougeron, David ; Heinemann, Volker ; Kisro, Jens ; Modest, Dominik Paul ; Schwaner, Ingo ; Arkosy, Péter ; Bodoky, György ; Csejtei, András ; Csöszi, Tibor ; Horvath, Zsolt ; Nagy, Zoltan ; Olah, Judith ; Pápai, Zsuzsanna ; Sipöcz, István ; Avallone, Antonio ; Banzi, Maria ; Bilancia, Domenico ; Ciardiello, Fortunato ; Cremolini, Chiara ; Lonardi, Sara ; Maiello, Evaristo ; Personeni, Nicola ; Scartozzi, Mario ; Duchnowska, Renata ; Itrych, Bartosz ; Karaszewska, Boguslawa ; Radecka, Barbara ; Rogowski, Wojciech ; Wyrwicz, Lucjan ; Wysocki, Piotr ; Fedyanin, Mikhail ; Kirtbaya, Dmitry ; Kislov, Nikolay ; Kopp, Mikhail ; Lebedeva, Ludmila ; Ledin, Evgeny ; Makarova, Yulia ; Moiseenko, Fedor ; Orlova, Rashida ; Radyukova, Irina ; Semiglazova, Tatiana ; Stroyakovskyi, Daniil ; Tjulandin, Sergei A ; ELEZ FERNANDEZ, MARIA ELENA; Ferreiro-Monteagudo, Reyes ; Grávalos-Castro, Cristina ; Polo-Marqués, Eduardo ; Pachón Olmos, Vanessa ; Ortiz-Morales, María José ; Rivera, Fernando ; Safont, María José ; Soler, Gemma ; TABERNERO CATURLA, JOSEP; Valladares Ayerbes, Manuel ; Virgili Manrique, Anna C ; Bondarekno, Igor ; Kolachko, Iryna ; Krulko, Stepan ; Ostapenko, Yuriy ; Paramonov, Viktor ; Ponomarova, Olga ; Ryspayeva, Dinara ; Shevnia, Serhii ; Shparyk, Yaroslav ; Bekaii-Saab, Tanios S ; Birhiray, Ruemu E ; Burhani, Nafisa ; Cruz-Correa, Marcia ; Cusnir, Mike ; Desai, Pratibha ; Fakih, Marwan G ; Hall, Ryan ; Jin, Zhaohui ; Jones, Jeremy C ; Lu, Jonathan ; Natarajan, Nagendra ; Shahinian, Haroutioun.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5. .10.1056/NEJMoa2214963
  32. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR  trial..Subbiah, Vivek ; Kreitman, Robert J ; Wainberg, Zev A ; Gazzah, Anas ; Lassen, Ulrik ; Stein, Alexander ; Wen, Patrick Y ; Dietrich, Sascha ; de Jonge, Maja J A ; Blay, Jean-Yves ; Italiano, Antoine ; Yonemori, Kan ; Cho, Daniel C ; de Vos, Filip Y F L ; Moreau, Philippe ; ELEZ FERNANDEZ, MARIA ELENA; Schellens, Jan H M ; Zielinski, Christoph C ; Redhu, Suman ; Boran, Aislyn ; Passos, Vanessa Q ; Ilankumaran, Palanichamy ; Bang, Yung-Jue.NATURE MEDICINE.1.1.82,9.30.10.1038/s41591-023-02321-8
  33. Seeking therapeutic synergy in BRAF mutant colorectal cancer..ELEZ FERNANDEZ, MARIA ELENA; ROS MONTAÑA, JAVIER; TABERNERO CATURLA, JOSEP.NATURE MEDICINE.1.1.82,9.4.10.1038/s41591-022-02192-5
  34. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine  tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study..Nesti, Cédric ; Bräutigam, Konstantin ; Benavent, Marta ; Bernal, Laura ; Boharoon, Hessa ; Botling, Johan ; Bouroumeau, Antonin ; Brcic, Iva ; Brunner, Maximilian ; Cadiot, Guillaume ; Camara, Maria ; Christ, Emanuel ; Clerici, Thomas ; Clift, Ashley K ; Clouston, Hamish ; Cobianchi, Lorenzo ; Cwikla, Jaroslaw B ; Daskalakis, Kosmas ; Frilling, Andrea ; Garcia-Carbonero, Rocio ; Grozinsky-Glasberg, Simona ; HERNANDO CUBERO, JORGE; Hervieu, Valérie ; Hofland, Johannes ; Holmager, Pernille ; Inzani, Frediano ; Jann, Henning ; Jimenez-Fonseca, Paula ; Kaçmaz, Enes ; Kaemmerer, Daniel ; Kaltsas, Gregory ; Klimacek, Branislav ; Knigge, Ulrich ; Kolasinska-Cwikla, Agnieszka ; Kolb, Walter ; Kos-Kudla, Beata ; Kunze, Catarina Alisa ; Landolfi, Stefania ; Rosa, Stefano La ; López, Carlos López ; Lorenz, Kerstin ; Matter, Maurice ; Mazal, Peter ; Mestre-Alagarda, Claudia ; Del Burgo, Patricia Morales ; van Dijkum, Els J M Nieveen ; Oleinikov, Kira ; Orci, Lorenzo A ; Panzuto, Francesco ; Pavel, Marianne ; Perrier, Marine ; Reims, Henrik Mikael ; Rindi, Guido ; Rinke, Anja ; Rinzivillo, Maria ; Sagaert, Xavier ; Satiroglu, Ilker ; Selberherr, Andreas ; Siebenhüner, Alexander R ; Tesselaar, Margot E T ; Thalhammer, Michael J ; Thiis-Evensen, Espen ; Toumpanakis, Christos ; Vandamme, Timon ; van den Berg, José G ; Vanoli, Alessandro ; van Velthuysen, Marie-Louise F ; Verslype, Chris ; Vorburger, Stephan A ; Lugli, Alessandro ; Ramage, John ; Zwahlen, Marcel ; Perren, Aurel ; Kaderli, Reto M.LANCET ONCOLOGY.1.1.51,1.18.10.1016/S1470-2045(22)00750-1
  35. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.Cortellini, Alessio ; TABERNERO CATURLA, JOSEP; Mukherjee, Uma ; Salazar, Ramon ; Sureda, Anna ; Maluquer, Clara ; Ferrante, Daniela ; Bower, Mark ; Sharkey, Rachel ; MIRALLAS VIÑAS, ORIOL; Plaja, Andrea ; Cucurull, Marc ; Mesia, Ricard ; Dalla Pria, Alessia ; Newsom-Davis, Thomas ; Van Hemelrijck, Mieke ; Sita-Lumsden, Ailsa ; Apthorp, Eleanor ; Vincenzi, Bruno ; Fazio, Giuseppina Rita Di ; Tonini, Giuseppe ; Pantano, Francesco ; Bertuzzi, Alexia ; Rossi, Sabrina ; Brunet, Joan ; Lambertini, Matteo ; Pedrazzoli, Paolo ; Biello, Federica ; D’Avanzo, Francesca ; Lee, Alvin J. X. ; Shawe-Taylor, Marianne ; Rogers, Lucy ; Murphy, Cian ; Cooper, Lee ; Andaleeb, Ramis ; Khalique, Saira ; Bawany, Samira ; Ahmed, Sarah ; Carmona-Garcia, M. Carmen ; Fort-Culillas, Roser ; Linan, Raquel ; Zoratto, Federica ; Rizzo, Gianpiero ; Perachino, Marta ; Doonga, Kris ; Gaidano, Gianluca ; Bruna, Riccardo ; Patriarca, Andrea ; Martinez-Vila, Clara ; Criado, Ignacio Perez ; Giusti, Raffaele ; Mazzoni, Francesca ; Antonuzzo, Lorenzo ; Santoro, Armando ; Parisi, Alessandro ; Queirolo, Paola ; Aujayeb, Avinash ; Rimassa, Lorenza ; Diamantis, Nikolaos ; Bertulli, Rossella ; Fulgenzi, Claudia A. M. ; D’Alessio, Antonio ; Ruiz-Camps, Isabel ; SAOUDI GONZALEZ, NADIA; GARCIA ILLESCAS, DAVID; Medina, Irene ; FOX, M. LAURA; Gennari, Alessandra ; AGUILAR COMPANY, JUAN; Pinato, David J. ; OnCovid Study Grp.LANCET ONCOLOGY.1.1.51,1.9.10.1016/S1470-2045(23)00056-6
  36. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS  wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a  multicentre, open-label, phase 2 study..Strickler, John H ; Cercek, Andrea ; Siena, Salvatore ; André, Thierry ; Ng, Kimmie ; Van Cutsem, Eric ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; ELEZ FERNANDEZ, MARIA ELENA; Bajor, David L ; Cremolini, Chiara ; Sanchez, Federico ; Stecher, Michael ; Feng, Wentao ; Bekaii-Saab, Tanios S ; MOUNTAINEER investigators ; Van Cutsem, Eric ; Peeters, Marc ; Van den Evnde, Marc ; André, Thierry ; Borg, Christophe ; Sarabi, Matthieu ; Ghiringhelli, Francois ; Chibaudel, Benoist ; Siena, Salvatore ; Cremolini, Chiara ; Zampino, Maria G ; ELEZ FERNANDEZ, MARIA ELENA; Keranen, Susana R ; Salazar, Ramon ; Alfonso, Pilar ; Strickler, John H ; Cercek, Andrea ; Ng, Kimmie ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; Bajor, David L ; Bekaii-Saab, Tanios S ; Gbolahan, Olumide ; Boland, Patrick ; Berg, Daniel ; Sanchez, Federico ; Goggins, Timothy ; Saeed, Anwar ; Burris, Howard ; Bendell, Johanna ; Outlaw, Darryl ; Tafur, Isaac ; Shergill, Ardaman ; Catenacci, Daniel ; Gong, Jun ; Garrido-Laguna, Ignacio ; Finley, Gene ; Weinberg, Benjamin ; Shields, Anthony ; Philip, Philip ; Turk, Anita ; Nguyen, Anthony ; Braiteh, Fadi ; Patel, Vijay ; Harwin, William ; Anderson, Ian ; Kundra, Ajay ; Chen, Christopher ; Ford, James ; Kundranda, Madappa ; Nguyen, Danny ; Ratnam, Suresh ; Richards, Donald ; Nallapareddy, Sujatha ; Beeram, Sridhar ; McKenney, Scott ; Shao, Spencer.LANCET ONCOLOGY.1.1.51,1.22.10.1016/S1470-2045(23)00150-X
  37. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic  colorectal cancer treated with BRAF combinatorial treatments..ROS MONTAÑA, JAVIER; MATITO ARIZA, JUDIT; VILLACAMPA JAVIERRE, GUILLERMO; COMAS NAVARRO, RAQUEL; GARCIA RODRIGUEZ, ARIADNA MARIA; Martini, G ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; Martin, Á ; Antista, M ; DE ALMEIDA TOLEDO, RODRIGO; Martinelli, E ; Pietrantonio, F ; Boccaccino, A ; Cremolini, C ; DIENSTMANN, RODRIGO; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; ELEZ FERNANDEZ, MARIA ELENA.ANNALS OF ONCOLOGY.1.1.50,5.8.10.1016/j.annonc.2023.02.016
  38. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus  Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic  Colorectal Cancer..Van Cutsem, Eric ; Taieb, Julien ; Yaeger, Rona ; Yoshino, Takayuki ; Grothey, Axel ; Maiello, Evaristo ; ELEZ FERNANDEZ, MARIA ELENA; Dekervel, Jeroen ; Ross, Paul ; Ruiz-Casado, Ana ; Graham, Janet ; Kato, Takeshi ; Ruffinelli, Jose C ; André, Thierry ; Carrière Roussel, Edith ; Klauck, Isabelle ; Groc, Mélanie ; Vedovato, Jean-Claude ; TABERNERO CATURLA, JOSEP.JOURNAL OF CLINICAL ONCOLOGY.1.1.45,4.19.10.1200/JCO.22.01693
  39. Early-Stage Breast Cancer Detection in Breast Milk..SAURA MANICH, CRISTINA; ORTIZ VELEZ, CAROLINA; MATITO ARIZA, JUDIT; ARENAS LAHUERTA, ENRIQUE HUERTA; SUÑOL CAMAS, ANNA; Martín, Ágatha ; Córdoba, Octavi ; MARTINEZ SABADELL, A; García-Ruiz, Itziar ; Miranda, Ignacio ; Morales-Comas, Clara ; CARRASCO LOPEZ, ESTELA; VIAPLANA DONATO, CRISTINA; PEG, VICENTE; NUCIFORO, PAOLO GIOVANNI; BAYO PUXAN, NEUS; Gonzalez-Medina, Alberto ; MIQUEL AYMAR, JOSEP MARIA; GOMEZ REY, MARINA; VILLACAMPA JAVIERRE, GUILLERMO; Arévalo, Silvia ; MUR ESPINOSA, ALEX; BALMAÑA GELPI, JUDITH; DIENSTMANN, RODRIGO; ARRIBAS LOPEZ, JOAQUIN VICENTE; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; SANSO MARTINEZ, MIRIAM.CANCER DISCOVERY.1.1.29,1.3.10.1158/2159-8290.CD-22-1340
  40. Hypoxia-Inducible Factor 2 Alpha (HIF2a) Inhibitors: Targeting Genetically Driven  Tumor Hypoxia..DE ALMEIDA TOLEDO, RODRIGO; Jimenez, Camilo ; Armaiz-Pena, Gustavo ; ARENILLAS LALLANA, CARLOTA; CAPDEVILA CASTILLON, JAUME; Dahia, Patricia L M.ENDOCRINE REVIEWS.1.1.20,3.9.10.1210/endrev/bnac025
  41. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine  neoplasms of gastroenteropancreatic and lung origin..CAPDEVILA, J ; HERNANDO CUBERO, JORGE; Teule, A ; Lopez, C ; Garcia-Carbonero, R ; Benavent, M ; Custodio, A ; GARCIA ALVAREZ, ALEJANDRO; Cubillo, A ; Alonso, V ; Carmona-Bayonas, A ; Alonso-Gordoa, T ; Crespo, G ; Jimenez-Fonseca, P ; Blanco, M ; Viudez, A ; La Casta, A ; Sevilla, I ; Segura, A ; Llanos, M ; LANDOLFI, STEFANIA; NUCIFORO, PAOLO GIOVANNI; Manzano, J L.NATURE COMMUNICATIONS.1.1.16,6.2.10.1038/s41467-023-38611-5
  42. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients  with HER2-expressing metastatic colorectal cancer..Yoshino, Takayuki ; Di Bartolomeo, Maria ; Raghav, Kanwal ; Masuishi, Toshiki ; Loupakis, Fotios ; Kawakami, Hisato ; Yamaguchi, Kensei ; Nishina, Tomohiro ; Wainberg, Zev ; ELEZ FERNANDEZ, MARIA ELENA; Rodriguez, Javier ; Fakih, Marwan ; Ciardiello, Fortunato ; Saxena, Kapil ; Kobayashi, Kojiro ; Bako, Emarjola ; Okuda, Yasuyuki ; Meinhardt, Gerold ; Grothey, Axel ; Siena, Salvatore ; DESTINY-CRC01 investigators ; Di Bartolomeo, Maria.NATURE COMMUNICATIONS.1.1.16,6.8.10.1038/s41467-023-38032-4
  43. Long-term platinum-based drug accumulation in cancer-associated fibroblasts  promotes colorectal cancer progression and resistance to therapy..Linares, Jenniffer ; Sallent-Aragay, Anna ; Badia-Ramentol, Jordi ; Recort-Bascuas, Alba ; Méndez, Ana ; Manero-Rupérez, Noemí ; Re, Daniele Lo ; Rivas, Elisa I ; Guiu, Marc ; Zwick, Melissa ; Iglesias, Mar ; Martinez-Ciarpaglini, Carolina ; Tarazona, Noelia ; Varese, Monica ; Hernando-Momblona, Xavier ; Cañellas-Socias, Adrià ; Orrillo, Mayra ; Garrido, Marta ; SAOUDI GONZALEZ, NADIA; ELEZ FERNANDEZ, MARIA ELENA; Navarro, Pilar ; TABERNERO CATURLA, JOSEP; Gomis, Roger R ; Batlle, Eduard ; Pisonero, Jorge ; Cervantes, Andres ; Montagut, Clara ; Calon, Alexandre.NATURE COMMUNICATIONS.1.1.16,6. .10.1038/s41467-023-36334-1
  44. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line  Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study..Vidal, Joana ; Fernández-Rodríguez, Maria Concepción ; Casadevall, David ; Garcia-Alfonso, Pilar ; Páez, David ; Guix, Marta ; Alonso, Vicente ; Cano, María Teresa ; Santos, Cristina ; Durán, Gema ; ELEZ FERNANDEZ, MARIA ELENA; Manzano, Jose Luis ; Garcia-Carbonero, Rocio ; Ferreiro-Monteagudo, Reyes ; Losa, Ferran ; Pineda, Estela ; Sastre, Javier ; Rivera, Fernando ; Bellosillo, Beatriz ; TABERNERO CATURLA, JOSEP; Aranda, Enrique ; Salazar, Ramon ; Montagut, Clara.CLINICAL CANCER RESEARCH.1.1.11,5.8.10.1158/1078-0432.CCR-22-1696
  45. Association of immune-related adverse events with the outcomes of immune  checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer..Nasca, Vincenzo ; Barretta, Francesco ; Corti, Francesca ; Lonardi, Sara ; Niger, Monica ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Jayachandran, Priya ; Shah, Aakash Tushar ; Salati, Massimiliano ; Fenocchio, Elisabetta ; Salvatore, Lisa ; Cremolini, Chiara ; ROS MONTAÑA, JAVIER; Ambrosini, Margherita ; Mazzoli, Giacomo ; Intini, Rossana ; Overman, Michael J ; Miceli, Rosalba ; Pietrantonio, Filippo.Journal for ImmunoTherapy of Cancer.1.2.10,9.2.10.1136/jitc-2022-005493
  46. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year  results of GEMCAD-1402..Pesántez, David ; Ten Hoorn, Sanne ; Machado, Isidro ; García-Albéniz, Xabier ; Rodríguez-Salas, Nuria ; Heredia-Soto, Victoria ; Viñal, David ; Pericay, Carles ; García-Carbonero, Rocio ; Losa, Ferran ; Alonso, Vicente ; Vera, Ruth ; Feliu Batlle, Jaime ; Gallego, Javier ; Salud, Antonieta ; Nogué, Miquel ; Layos, Laura ; Montagut, Clara ; CAPDEVILA CASTILLON, JAUME; Vermeulen, Louis ; Maurel, Joan ; Fernandez-Martos, Carlos.JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.1.2.10,3. .10.1093/jnci/djad120
  47. Locoregional Failure During and After Short-course Radiotherapy Followed by  Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery:  A 5-Year Follow-up of the RAPIDO Trial..Dijkstra, Esmée A ; Nilsson, Per J ; Hospers, Geke A P ; Bahadoer, Renu R ; Meershoek-Klein Kranenbarg, Elma ; Roodvoets, Annet G H ; Putter, Hein ; Berglund, Åke ; Cervantes, Andrés ; Crolla, Rogier M P H ; Hendriks, Mathijs P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, Ibrahim ; Marijnen, Corrie A M ; van de Velde, Cornelis J H ; Glimelius, Bengt ; van Etten, Boudewijn ; and collaborative investigators.ANNALS OF SURGERY.1.1.10,1.34.10.1097/SLA.0000000000005799
  48. Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of  different locations: data from the SEPTRALU study..Mitjavila, Mercedes ; Jimenez-Fonseca, Paula ; Belló, Pilar ; Pubul, Virginia ; Percovich, Juan Carlos ; Garcia-Burillo, Amparo ; HERNANDO CUBERO, JORGE; Arbizu, Javier ; Rodeño, Emilia ; Estorch, Montserrat ; Llana, Belén ; Castellón, Maribel ; García-Cañamaque, Lina ; Gajate, Pablo ; Riesco, Maria Carmen ; Miguel, Maria Begoña ; Balaguer-Muñoz, David ; Custodio, Ana ; Cano, Juana María ; Repetto, Alexandra ; Garcia-Alonso, Pilar ; Muros, Maria Angustias ; Vercher-Conejero, Jose Luis ; Carmona-Bayonas, Alberto.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.1.1.9,1.5.10.1007/s00259-023-06166-8
  49. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the  Spanish Registry of Essential Thrombocythemia..Alvarez-Larrán, Alberto ; Cuevas, Beatriz ; Velez, Patricia ; Noya, Soledad ; Caballero-Navarro, Gonzalo ; Ferrer-Marín, Francisca ; Carbonell, Sara ; Pérez-Encinas, Manuel ; Gómez-Casares, María Teresa ; Pérez-López, Raúl ; Magro, Elena ; Moretó, Ana ; Pastor-Galán, Irene ; Angona, Anna ; Mata-Vázquez, María Isabel ; Guerrero-Fernández, Lucía ; Guerra, José María ; Carreño-Tarragona, Gonzalo ; FOX, M. LAURA; Murillo, Ilda ; García-Gutiérrez, Valentín ; Mora, Elvira ; Stuckey, Ruth ; Arellano-Rodrigo, Eduardo ; Hernández-Boluda, Juan Carlos ; Pereira, Arturo.Hemasphere.1.2.9,1. .10.1097/HS9.0000000000000936
  50. Liver transplantation in metastatic colorectal cancer: are we ready for it?.ROS MONTAÑA, JAVIER; SALVA BALLABRERA, FRANCESC; Dopazo, Cristina ; López, Daniel ; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; Charco, Ramon ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.BRITISH JOURNAL OF CANCER.1.2.8,8.3.10.1038/s41416-023-02213-1
  51. DPPA3-HIF1a axis controls colorectal cancer chemoresistance by imposing a slow  cell-cycle phenotype..CUESTA BORRAS, ESTEFANIA; SALVANS GORJON, CANDIDA; ARQUES CASAMITJANA, ORIOL; CHICOTE RAMOS, IRENE; RAMIREZ CORPAS, LORENA; CABELLOS ALONSO, LAIA; MARTINEZ-QUINTANILLA MARTINEZ, JORDI; MUR ESPINOSA, ALEX; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; Tejedor, Juan Ramón ; MIRALLAS VIÑAS, ORIOL; ELEZ FERNANDEZ, MARIA ELENA; Fraga, Mario F ; TABERNERO CATURLA, JOSEP; NUCIFORO, PAOLO GIOVANNI; CAPDEVILA CASTILLON, JAUME; GARCIA PALMER, HECTOR; PUIG BORREIL, ISABEL.CELL REPORTS.1.2.8,8.0.10.1016/j.celrep.2023.112927
  52. Efficacy and safety of immune checkpoint inhibitors in young adults with  metastatic melanoma..Wong, Selina K ; Blum, Steven M ; Sun, Xiaopeng ; Da Silva, Inês P ; Zubiri, Leyre ; Ye, Fei ; Bai, Kun ; Zhang, Kevin ; Ugurel, Selma ; Zimmer, Lisa ; Livingstone, Elisabeth ; Schadendorf, Dirk ; Serra-Bellver, Patricio ; MUÑOZ COUSELO, EVA; ORTIZ VELEZ, CAROLINA; LOSTES, MARIA JULIA; Huertas, Roberto M ; Arance, Ana ; Pickering, Lisa ; Long, Georgina V ; Carlino, Matteo S ; Buchbinder, Elizabeth I ; Vázquez-Cortés, Leticia ; Jara-Casas, Diego ; Márquez-Rodas, Iván ; González-Espinoza, Iván R ; Balko, Justin M ; Menzies, Alexander M ; Sullivan, Ryan J ; Johnson, Douglas B.EUROPEAN JOURNAL OF CANCER.1.2.8,4.3.10.1016/j.ejca.2022.12.013
  53. Pembrolizumab for previously treated, microsatellite instability-high/mismatch  repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164..Le, Dung T ; Diaz, Luis A Jr ; Kim, Tae Won ; Van Cutsem, Eric ; Geva, Ravit ; Jäger, Dirk ; Hara, Hiroki ; Burge, Matthew ; O’Neil, Bert H ; Kavan, Petr ; Yoshino, Takayuki ; Guimbaud, Rosine ; Taniguchi, Hiroya ; ELEZ FERNANDEZ, MARIA ELENA; Al-Batran, Salah-Eddin ; Boland, Patrick M ; Cui, Yi ; Leconte, Pierre ; Marinello, Patricia ; André, Thierry.EUROPEAN JOURNAL OF CANCER.1.2.8,4.8.10.1016/j.ejca.2023.02.016
  54. Sex differences on multikinase inhibitors toxicity in patients with advanced  gastroenteropancreatic neuroendocrine tumours..HERNANDO CUBERO, JORGE; ROCA HERRERA, MARIA; GARCIA ALVAREZ, ALEJANDRO; Raymond, Eric ; Ruszniewski, Philippe ; Kulke, Matthew H ; Grande, Enrique ; García-Carbonero, Rocío ; Castellano, Daniel ; Salazar, Ramón ; Ibrahim, Toni ; Teule, Alex ; Alonso, Vicente ; Fazio, Nicola ; Valle, Juan W ; Tafuto, Salvatore ; CARMONA HEREDIA, Mª ANGELES; NAVARRO GARCES, VICTOR; CAPDEVILA CASTILLON, JAUME.EUROPEAN JOURNAL OF CANCER.1.2.8,4.1.10.1016/j.ejca.2023.04.013
  55. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome  post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey..van Doesum, Jaap A ; Salmanton-García, Jon ; Marchesi, Francesco ; Di Blasi, Roberta ; Falces-Romero, Iker ; CABIRTA, ALBA; Farina, Francesca ; Besson, Caroline ; Weinbergerová, Barbora ; Van Praet, Jens ; Schönlein, Martin ; Lopez-Garcia, Alberto ; Lamure, Sylvain ; Guidetti, Anna ; De Ramón-Sánchez, Cristina ; Batinic, Josip ; Gavriilaki, Eleni ; Tragiannidis, Athanasios ; Tisi, Maria Chiara ; Plantefeve, Gaëtan ; Petzer, Verena ; Ormazabal-Velez, Irati ; Marques de Almeida, Joyce ; Marchetti, Monia ; Maertens, Johan A ; Machado, Marina ; Kulasekararaj, Austin G ; Hernández-Rivas, José Ángel ; Gomes da Silva, Maria ; Fernández, Noemí ; Espigado, Ildefonso ; Drgona, Lubos ; Dragonetti, Giulia ; Metafuni, Elisabetta ; Calbacho, Maria ; Blennow, Ola ; Wolf, Dominik ; van Anrooij, Bjorn ; Nunes Rodrigues, Raquel ; Nordlander, Anna ; Martín-González, Juan-Alberto ; Lievin, Raphaël ; JIMENEZ BALAREZO, MARIA MORAIMA DEL CARMEN; Grafe, Stefanie K ; Garcia-Sanz, Ramon ; Córdoba, Raúl ; Rahimli, Laman ; van Meerten, Tom ; Cornely, Oliver A ; Pagano, Livio.Blood Advances.1.2.7,6.7.10.1182/bloodadvances.2022009578
  56. A signature of circulating microRNAs predicts the response to treatment with  FOLFIRI plus aflibercept in metastatic colorectal cancer patients..Toledano-Fonseca, M ; Gómez-España, M A ; ELEZ FERNANDEZ, MARIA ELENA; Grávalos, C ; García-Alfonso, P ; Rodríguez, R ; Losa, F ; Alés Díaz, I ; Graña, B ; Valladares-Ayerbes, M ; García-Ortiz, M V ; Polo, E ; Salgado, M ; Rivera, F ; Safont, M J ; Salud, A ; Ruiz-Casado, A ; TABERNERO CATURLA, JOSEP; Riesco, M C ; Rodríguez-Ariza, A ; Aranda, E ; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).BIOMEDICINE & PHARMACOTHERAPY.1.1.7,5.2.10.1016/j.biopha.2023.114272
  57. Establishment of patient-derived tumor organoids to functionally inform treatment  decisions in metastatic colorectal cancer..Martini, G ; Belli, V ; Napolitano, S ; Ciaramella, V ; Ciardiello, D ; Belli, A ; Izzo, F ; Avallone, A ; Selvaggi, F ; Menegon Tasselli, F ; Santaniello, W ; Franco, R ; PUIG BORREIL, ISABEL; RAMIREZ CORPAS, LORENA; CHICOTE RAMOS, IRENE; MANCUSO, FRANCESCO MATTIA; CARATU, GINEVRA; Serres, X ; FASANI, ROBERTA; JIMENEZ, JOSE; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; Mulet, N ; Della Corte, C M ; Troiani, T ; VIVANCOS PRELLEZO, ANA; DIENSTMANN, RODRIGO; ELEZ FERNANDEZ, MARIA ELENA; GARCIA PALMER, HECTOR; TABERNERO CATURLA, JOSEP; Martinelli, E ; Ciardiello, F ; ARGILES MARTINEZ, GUILLERMO.ESMO open.1.2.7,3.5.10.1016/j.esmoop.2023.101198
  58. Sex and gender perspectives in colorectal cancer..BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; RODRIGUEZ CASTELLS, MARTA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.ESMO open.1.2.7,3.9.10.1016/j.esmoop.2023.101204
  59. The value of post-operative chemotherapy after chemoradiotherapy in patients with  high-risk locally advanced rectal cancer-results from the RAPIDO trial..Dijkstra, E A ; Zwart, W H ; Nilsson, P J ; Putter, H ; Roodvoets, A G H ; Meershoek-Klein Kranenbarg, E ; Frödin, J E ; Nygren, P ; Østergaard, L ; Kersten, C ; Verbiené, I ; Cervantes, A ; Hendriks, M P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, I ; van de Velde, C J H ; Marijnen, C A M ; van Etten, B ; Hospers, G A P ; Glimelius, B ; collaborative investigators.ESMO open.1.2.7,3.1.10.1016/j.esmoop.2023.101158
  60. Genomically matched therapy in refractory colorectal cancer according to ESMO  Scale for Clinical Actionability of Molecular Targets: experience of a  comprehensive cancer centre network..Margalef, Núria Mulet ; Castillo, Carmen ; Mosteiro, Miguel ; Pérez, Xavier ; AGUILAR IZQUIERDO, SUSANA; RUIZ PACE, FIORELLA DAFNE; Gil, Marta ; Cuadra, Carmen ; Ruffinelli, José Carlos ; Martínez, Mercedes ; Losa, Ferran ; Soler, Gema ; Teulé, Àlex ; Castany, Roser ; Gallego, Rosa ; Ruíz, Andrea ; GARRALDA CABANAS, ELENA; ELEZ FERNANDEZ, MARIA ELENA; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; Salazar, Ramon ; DIENSTMANN, RODRIGO; Santos, Cristina.MOLECULAR ONCOLOGY.1.3.6,6.0.10.1002/1878-0261.13444
  61. Efficacy and safety of pembrolizumab monotherapy in patients with advanced  thyroid cancer in the phase 2 KEYNOTE-158 study..Oh, Do-Youn ; Algazi, Alain ; CAPDEVILA CASTILLON, JAUME; Longo, Federico ; Miller, Wilson Jr ; Chun Bing, Jerry Tan ; Bonilla, Carlos Eduardo ; Chung, Hyun Cheol ; Guren, Tormod K ; Lin, Chia-Chi ; Motola-Kuba, Daniel ; Shah, Manisha ; Hadoux, Julien ; Yao, Lili ; Jin, Fan ; Norwood, Kevin ; Lebellec, Loïc.CANCER.1.3.6,2.4.10.1002/cncr.34657
  62. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell  vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal  cancer patients; GEMCAD 1602 study..Español-Rego, Marta ; Fernández-Martos, Carlos ; ELEZ FERNANDEZ, MARIA ELENA; Foguet, Carles ; Pedrosa, Leire ; Rodríguez, Nuria ; Ruiz-Casado, Ana ; Pineda, Estela ; Cid, Joan ; Cabezón, Raquel ; Oliveres, Helena ; Lozano, Miquel ; Ginés, Angels ; García-Criado, Angeles ; Ayuso, Juan Ramon ; Pagés, Mario ; Cuatrecasas, Miriam ; Torres, Ferràn ; Thomson, Timothy ; Cascante, Marta ; Benítez-Ribas, Daniel ; Maurel, Joan.CANCER IMMUNOLOGY IMMUNOTHERAPY.1.3.5,8.3.10.1007/s00262-022-03283-5
  63. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF  V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer..TABERNERO CATURLA, JOSEP; Van Cutsem, Eric ; GARRALDA CABANAS, ELENA; Tai, David ; De Braud, Filippo ; Geva, Ravit ; van Bussel, Mark T J ; Fiorella Dotti, Katia ; Elez, Elena ; de Miguel, María J ; Litwiler, Kevin ; Murphy, Danielle ; Edwards, Michelle ; Morris, Van Karlyle.ONCOLOGIST.1.3.5,8.7.10.1093/oncolo/oyad007
  64. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR  Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors..Colle, Raphael ; Lonardi, Sara ; Cachanado, Marine ; Overman, Michael J ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Corti, Francesca ; Jayachandran, Priya ; Svrcek, Magali ; Dardenne, Antoine ; Cervantes, Baptiste ; Duval, Alex ; Cohen, Romain ; Pietrantonio, Filippo ; André, Thierry.ONCOLOGIST.1.3.5,8.5.10.1093/oncolo/oyad082
  65. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus  Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer..Van Cutsem, Eric ; Yaeger, Rona ; Delord, Jean-Pierre ; TABERNERO CATURLA, JOSEP; Siu, Lillian L ; Ducreux, Michel ; Siena, Salvatore ; ELEZ FERNANDEZ, MARIA ELENA; Kasper, Stefan ; Zander, Thomas ; Steeghs, Neeltje ; Murphy, Danielle ; Edwards, Michelle ; Wainberg, Zev A.ONCOLOGIST.1.3.5,8.0.10.1093/oncolo/oyad210
  66. Pembrolizumab in Asian patients with  microsatellite-instability-high/mismatch-repair-deficient colorectal cancer..Yoshino, Takayuki ; Andre, Thierry ; Kim, Tae Won ; Yong, Wei Peng ; Shiu, Kai-Keen ; Jensen, Benny Vittrup ; Jensen, Lars Henrik ; Punt, Cornelis J A ; Smith, Denis ; Garcia-Carbonero, Rocio ; Alcaide-Garcia, Julia ; Gibbs, Peter ; de la Fouchardiere, Christelle ; Rivera, Fernando ; ELEZ FERNANDEZ, MARIA ELENA; Le, Dung T ; Adachi, Noriaki ; Fogelman, David ; Marinello, Patricia ; Diaz, Luis A Jr.CANCER SCIENCE.2.3.5,7.4.10.1111/cas.15650
  67. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The  Ongoing Search for Biomarkers..ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; Rodriguez, Marta ; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.2.10.3390/cancers15174245
  68. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution,  and Clinical Implications..SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; RODRIGUEZ CASTELLS, MARTA; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaráz, Adriana ; Vega, Sharela ; Bueno, Sergio ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.0.10.3390/cancers15164020
  69. Impact of the COVID-19 pandemic in the early-onset colorectal cancer..BARAIBAR ARGOTA, IOSUNE; GARCIA RODRIGUEZ, ARIADNA MARIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; COMAS NAVARRO, RAQUEL; Castillo, Gloria ; Sanchis, Mireia ; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; CAPDEVILA CASTILLON, JAUME; Castells, Marta R ; Martí, Marc ; LANDOLFI, STEFANIA; Espín, Eloy ; Navalpotro, Begoña ; Guevara, Jorge ; Dopazo, Cristina ; NUCIFORO, PAOLO GIOVANNI; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Translational Oncology.2.4.5.1.10.1016/j.tranon.2023.101668
  70. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line  Treatment..Andreatos, Nikolaos ; McGarrah, Patrick W ; Sonbol, Mohamad Bassam ; Starr, Jason S ; CAPDEVILA CASTILLON, JAUME; Sorbye, Halfdan ; Halfdanarson, Thorvardur R.CURRENT ONCOLOGY REPORTS.2.4.4,7.0.10.1007/s11912-023-01438-w
  71. Use of lenvatinib in the treatment of radioiodine-refractory differentiated  thyroid cancer: a multidisciplinary perspective for daily practice..CAPDEVILA CASTILLON, JAUME; Deandreis, Desiree’ ; Durante, Cosimo ; Leboulleux, Sophie ; Luster, Markus ; Netea-Maier, Romana ; Newbold, Kate ; Singer, Susanne ; Sykiotis, Gerasimos P ; Bartes, Beate ; Farnell, Kate ; Locati, Laura Deborah.European Thyroid Journal.2.3.4,7.0.10.1530/ETJ-23-0068
  72. Advances in immune checkpoint inhibitor combination strategies for microsatellite  stable colorectal cancer..ROS MONTAÑA, JAVIER; Balconi, Francesca ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.9.10.3389/fonc.2023.1112276
  73. Current perspectives on the management of patients with advanced RET-driven  thyroid cancer in Europe..Elisei, Rossella ; Grande, Enrique ; Kreissl, Michael C ; Leboulleux, Sophie ; Puri, Tarun ; Fasnacht, Nicolas ; CAPDEVILA CASTILLON, JAUME.Frontiers in oncology.2.4.4,7.1.10.3389/fonc.2023.1141314
  74. The impact of clinical and translational research on the quality of life during  the metastatic colorectal cancer patient journey..RODRIGUEZ CASTELLS, MARTA; BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaraz, Adriana ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.0.10.3389/fonc.2023.1272561
  75. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch  Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer  Treated With Target Therapy or Chemotherapy..Moretto, Roberto ; Germani, Marco Maria ; ROS MONTAÑA, JAVIER; Daniel, Francesca ; Ghelardi, Filippo ; Vetere, Guglielmo ; Giordano, Mirella ; DE ALMEIDA TOLEDO, RODRIGO; Bergamo, Francesca ; Randon, Giovanni ; ELEZ FERNANDEZ, MARIA ELENA; Lonardi, Sara ; Pietrantonio, Filippo ; Vignali, Paola ; Rossini, Daniele ; MATITO ARIZA, JUDIT; Ugolini, Clara ; Fontanini, Gabriella ; Masi, Gianluca ; Cremolini, Chiara.Jco Precision Oncology.2.4.4,6. .10.1200/PO.23.00255
  76. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the  INTENSIVE study..Fazio, Nicola ; Gervaso, Lorenzo ; Halfdanarson, Thorvardur R ; Sonbol, Mohamad ; Eiring, Rachel A ; Pusceddu, Sara ; Prinzi, Natalie ; Lombardi Stocchetti, Benedetta ; Grozinsky-Glasberg, Simona ; Gross, David J ; Walter, Thomas ; Robelin, Patrick ; Lombard-Bohas, Catherine ; Frassoni, Samuele ; Bagnardi, Vincenzo ; Antonuzzo, Lorenzo ; Sparano, Clotilde ; Massironi, Sara ; Gelsomino, Fabio ; Bongiovanni, Alberto ; Ranallo, Nicoletta ; Tafuto, Salvatore ; Rossi, Maura ; Cives, Mauro ; Rasul Kakil, Ibrahim ; Hamid, Hytam ; Chirco, Alessandra ; Squadroni, Michela ; La Salvia, Anna ; HERNANDO CUBERO, JORGE; Hofland, Johannes ; Koumarianou, Anna ; Boselli, Sabrina ; Tamayo, Darina ; Mazzon, Cristina ; Rubino, Manila ; Spada, Francesca.ENDOCRINE-RELATED CANCER.2.5.3,9.0.10.1530/ERC-22-0395
  77. Current professional standing of young medical oncologists in Spain: a nationwide  survey by the Spanish Society of Medical Oncology + MIR section..Martinez, Domingo Antonio Sanchez ; Quilez-Cutillas, Aliica ; Jimenez-Labaig, Pablo ; Sesma, Andrea ; Tarazona, Noelia ; Pacheco-Barcia, Vilma ; Obispo, Berta ; Paez, David ; Quintanar, Teresa ; Sanchez-Canovas, Manuel ; Montes, Ana Fernandez ; FELIP FONT, ENRIQUETA; Rodriguez-Lescure, Alvaro ; ELEZ FERNANDEZ, MARIA ELENA.CLINICAL & TRANSLATIONAL ONCOLOGY.3.6.3,4.1.10.1007/s12094-022-02989-3
  78. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and  biomarkers..ROS MONTAÑA, JAVIER; RODRIGUEZ CASTELLS, MARTA; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.EXPERT REVIEW OF ANTICANCER THERAPY.3.6.3,3.3.10.1080/14737140.2023.2236794
  79. Satisfaction with injection experience of patients with neuroendocrine tumors  enrolled on lanreotide autogel patient support programs: Results from the  international HomeLAN survey..HERNANDO CUBERO, JORGE; Kolarova, Teodora ; Verslype, Chris ; Kaltsas, Gregory ; Houchard, Aude ; Gueguen, Delphine ; De Herder, Wouter W.JOURNAL OF NEUROENDOCRINOLOGY.3.6.3,2.0.10.1111/jne.13281
  80. Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study.Grande, Enrique ; Moreno, Fernando ; Trigo, Jose ; CAPDEVILA CASTILLON, JAUME; Abiles, Jimena ; Sirvent, Mariola ; Garrido-Siles, Margarita ; Olveira, Gabriel ; Ocon, Julia ; Soto, Maria Luisa Fernandez.SUPPORTIVE CARE IN CANCER.1.3.3,1.0.10.1007/s00520-023-08004-x
  81. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize  immuno-oncology combinations in early-phase trials..HERNANDO CALVO, ALBERTO; VILA CASADESUS, MARIA; Bareche, Yacine ; Gonzalez-Medina, Alberto ; Abbas-Aghababazadeh, Farnoosh ; LO GIACCO, DEBORA GRAZIA; MARTIN CASADO, AGATHA; SAAVEDRA SANTAGADEA, OMAR; BRAÑA GARCIA, IRENE; VIEITO VILLAR, MARIA; FASANI, ROBERTA; Stagg, John ; MANCUSO, FRANCESCO MATTIA; Haibe-Kains, Benjamin ; Han, Ming ; BERCHE BARCELO, ROGER; Pugh, Trevor J ; MIRALLAS VIÑAS, ORIOL; JIMENEZ, JOSE; SAOUDI GONZALEZ, NADIA; VALVERDE MORALES, CLAUDIA M; MUÑOZ COUSELO, EVA; SUAREZ RODRIGUEZ, CRISTINA; DIEZ GARCIA, MARC; ELEZ FERNANDEZ, MARIA ELENA; CAPDEVILA CASTILLON, JAUME; OAKNIN BENZAQUEN, ANA MAZALTOB; SAURA MANICH, CRISTINA; MACARULLA MERCADE, TERESA; CARLES GALCERAN, JOAN; FELIP FONT, ENRIQUETA; DIENSTMANN, RODRIGO; Bedard, Philippe L ; NUCIFORO, PAOLO GIOVANNI; SEOANE SUAREZ, JOAN; TABERNERO CATURLA, JOSEP; GARRALDA CABANAS, ELENA; VIVANCOS PRELLEZO, ANA.Med. . . .0.10.1016/j.medj.2023.07.006
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required